Monocyte chemoattractant protein-1 (MCP-1, CCL-2) binds to the Duffy antigen (DARC) on red blood cells, which act as a sink for several chemokines including MCP-1. In this study it is hypothesized that DARC may alter the pharmacokinetics of infused recombinant human MCP-1 (rhMCP-1). The primary aim of this first in man trial is to compare the pharmacokinetics of rhMCP-1 in Duffy positive and negative individuals. A randomized, double-blinded, placebo-controlled dose escalation trial was conducted on 36 healthy volunteers. Subjects received infusions of 0.02–2.0 μg/kg rhMCP-1 or placebo for one hour. RhMCP-1 displayed linear pharmacokinetics. Duffy negative individuals reached maximal plasma levels significantly earlier, but overall plasma concentration profiles were not altered. rhMCP-1 markedly increased monocyte counts, and estimated EC50 values were 10-fold higher in Duffy positive than in Duffy negative subjects. Increased monocyte counts were associated with decreased surface expression of intercellular adhesion molecule 1 (ICAM-1, CD54). In contrast, neither CCR-2 or CD11b expression, nor markers of platelet or endothelial activation, inflammation and coagulation were altered. RhMCP-1 is a highly selective chemoattractant for monocytes in humans. The Duffy antigen only minimally alters the pharmacokinetics of rhMCP-1 for doses up to 2 μg/kg.
WeitzJIByrneJClagettGP. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: A critical review. Circulation1996; 94:3026–49.
3.
RegensteinerJGStewartKJ. Established and evolving medical therapies for claudication in patients with peripheral arterial disease. Nat Clin Pract Cardiovasc Med2006; 3:604–10.
4.
HoeferIEvan RoyenNBuschmannIRPiekJJSchaperW. Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc Res2001; 49:609–17.
5.
ItoWDArrasMWinklerBScholzDSchaperJSchaperW. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res1997; 80:829–37.
6.
VoskuilMvan RoyenNHoeferIE. Modulation of collateral artery growth in a porcine hind limb ligation model using MCP-1. Am J Physiol Heart Circ Physiol2003; 284:1422–8.
7.
HorukRWangZXPeiperSCHesselgesserJ. Identification and characterization of a promiscuous chemokine-binding protein in a human erythroleukemic cell line. J Biol Chem1994; 269:17730–3.
8.
ChaudhuriAZbrzeznaVPolyakovaJPogoAOHesselgesserJHorukR. Expression of the Duffy antigen in K562 cells. Evidence that it is the human erythrocyte chemokine receptor. J Biol Chem1994; 269:7835–8.
9.
LeeJSFrevertCWWurfelMM. Duffy antigen facilitates movement of chemokine across the endothelium in vitro and promotes neutrophil transmigration in vitro and in vivo. J Immunol2003; 170:5244–51.
10.
Jilma-StohlawetzPHomoncikMDruckerC. Fy phenotype and gender determine plasma levels of monocyte chemotactic protein. Transfusion2001; 41:378–81.
11.
MayrFBSpielAOLeitnerJM. Duffy antigen modifies the chemokine response in human endotoxemia. Crit Care Med2008; 36:159–65.
12.
JilmaBMarsikCMayrF. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther2002; 72:403–10.
13.
RodbardD. Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin Chem1974; 20:1255–70.
14.
LeitnerJMFirbasCMayrFBReiterRASteinlechnerBJilmaB. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin Pharmacol Ther2006; 79:23–34.
15.
HergovichNAignerMEichlerHGEntlicherJDruckerCJilmaB. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther2000; 68:435–42.
16.
JilmaBVoltmannJAlbinniS. Dexamethasone down-regulates the expression of L-selectin on the surface of neutrophils and lymphocytes in humans. Clin Pharmacol Ther1997; 62:562–8.
17.
GavrilinMADeucherMFBoeckmanFKolattukudyPE. Monocyte chemotactic protein 1 upregulates IL-1beta expression in human monocytes. Biochem Biophys Res Commun2000; 277:37–42.
18.
DerhaschnigUBergmairDMarsikCSchlifkeIWijdenesJJilmaB. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit Care Med2004; 32:1136–40.
19.
MillerMASagnellaGAKerrySMStrazzulloPCookDGCappuccioFP. Ethnic differences in circulating soluble adhesion molecules: The Wandsworth Heart and Stroke Study. Clin Sci (Lond)2003; 104:591–8.
20.
FreedmanDSGatesLFlandersWD. Black/white differences in leukocyte subpopulations in men. Int J Epidemiol1997; 26:757–64.
21.
HilbertJSchneeJRummerstorferUJilmaB. Pharmacokinetics and Pharmacodynamics of BIWH 3 in healthy Duffy antigen positive and Duffy antigen negative male volunteers. Abstract accepted for presentation 2006 ASCPT National Meeting 2006.
22.
FukumaNAkimitsuNHamamotoHKusuharaHSugiyamaYSekimizuK. A role of the Duffy antigen for the maintenance of plasma chemokine concentrations. Biochem Biophys Res Commun2003; 303:137–9.
23.
JilmaBAkimitsuNFukumaNSekimizuKJilma-StohlawetzP. Man, mouse and Duffy genotype-phenotype-specific pharmacokinetics of monocyte chemotactic protein-1. Transfus Med2004; 14:251–2.
24.
van RoyenNHoeferIBottingerM. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ Res2003; 92:218–25.
25.
PapadopoulouCCorrigallVTaylorPRPostonRN. The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine2008; 43:181–6.
26.
HoogeveenRCMorrisonABoerwinkleE. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis2005; 183:301–7.
27.
JiangYBellerDIFrendlGGravesDT. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol1992; 148:2423–8.
28.
TakahashiKMizuaraiSArakiH. Adiposity elevates plasma MCP-1 levels leading to the increased CD lib-positive monocytes in mice. J Biol Chem2003; 278:46654–60.
29.
VaddiKNewtonRC. Regulation of monocyte integrin expression by beta-family chemokines. J Immunol1994; 153:4721–32.
30.
AudranRLesimpleTDelamaireMPicotCVan DammeJToujasL. Adhesion molecule expression and response to chemotactic agents of human monocyte-derived macrophages. Clin Exp Immunol1996; 103:155–60.
31.
van EedenSFGrantonJHardsJMMooreBHoggJC. Expression of the cell adhesion molecules on leukocytes that demarginate during acute maximal exercise. J Appl Physiol1999; 86:970–6.
32.
TangiralaRKMuraoKQuehenbergerO. Regulation of expression of the human monocyte chemotactic protein-1 receptor (hCCR2) by cytokines. J Biol Chem1997; 272:8050–6.
33.
RoldanVMarinFLipGYBlannAD. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost2003; 90:1007–20.
34.
BlannADNadarSKLipGY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J2003; 24:2166–79.
35.
MlekuschWExnerMSchillingerM. E-Selectin and restenosis after femoropopliteal angioplasty: Prognostic impact of the Ser128Arg genotype and plasma levels. Thromb Haemost2004; 91:171–9.
36.
TanKTTayebjeeMHLyndCBlannADLipGY. Platelet microparticles and soluble P selectin in peripheral artery disease: Relationship to extent of disease and platelet activation markers. Ann Med2005; 37:61–6.
37.
GuLOkadaYClintonSK. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell1998; 2:275–81.
38.
BoringLGoslingJClearyMCharoIF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature1998; 394:894–7.
